<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04237792</url>
  </required_header>
  <id_info>
    <org_study_id>C0801039</org_study_id>
    <nct_id>NCT04237792</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Dexmedetomidine (DEX) for Sedation of Subjects ≥1 Month to &lt;17 Years Undergoing MRI Scans</brief_title>
  <official_title>A PHASE 3/4 RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING STUDY OF THE SAFETY AND EFFICACY OF DEXMEDETOMIDINE (DEX) USED WITH PROPOFOL (PRO) AS NEEDED FOR PROCEDURAL SEDATION OF PEDIATRIC SUBJECTS ≥1 MONTH TO &lt;17 YEARS OF AGE UNDERGOING MRI SCANS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, dose-ranging study of the efficacy and safety of
      dexmedetomidine (DEX) when used with propofol as needed, for procedural sedation of pediatric
      subjects ≥1 month to &lt;17 years of age undergoing MRI scans in the US and Japan.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of subjects at the DEX high dose level versus the low dose level who do not require concomitant PRO to complete the MRI</measure>
    <time_frame>baseline up to 2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects at the DEX high dose level versus the low dose level in each age cohort who do not require concomitant PRO to complete the MRI</measure>
    <time_frame>baseline up to 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects at the DEX middle dose level compared to the high dose level and the low dose level in both the overall sample and in each age cohort who do not require concomitant PRO to complete the MRI</measure>
    <time_frame>baseline up to 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of time at the target sedation rating scale score (Pediatric Sedation State Scale [PSSS] rating of 2) after the administration of the DEX loading dose and during the DEX maintenance infusion</measure>
    <time_frame>baseline up to 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amount of time from the start of the DEX loading dose infusion to the time of the first PRO bolus administration</measure>
    <time_frame>baseline up to 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergence time (defined as the time from the end of the MRI scan to when the subject meets a Modified Aldrete Score ≥9)</measure>
    <time_frame>post-procedure up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects at each DEX dose level who receive PRO</measure>
    <time_frame>baseline up to 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount (mg/kg) and weight and time adjusted amount (per kg per minute basis) of concomitant PRO required to successfully complete the MRI scan</measure>
    <time_frame>baseline up to 2 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>MRI Sedation</condition>
  <arm_group>
    <arm_group_label>dexmedetomidine low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose of dexmedetomidine to be given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine middle dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>middle dose of dexmedetomidine to be given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine high dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose of dexmedetomidine to be given</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine</intervention_name>
    <description>dexmedetomidine low, middle and high doses are provided as an intravenous bolus loading dose followed by an intravenous maintenance dose infusion throughout the MRI scan</description>
    <arm_group_label>dexmedetomidine high dose group</arm_group_label>
    <arm_group_label>dexmedetomidine low dose group</arm_group_label>
    <arm_group_label>dexmedetomidine middle dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol</intervention_name>
    <description>propofol IV administration will be given if needed to maintain sedation</description>
    <arm_group_label>dexmedetomidine high dose group</arm_group_label>
    <arm_group_label>dexmedetomidine low dose group</arm_group_label>
    <arm_group_label>dexmedetomidine middle dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Male or female subject ≥1 month and &lt;17 years of age.

          2. American Society of Anesthesiologists (ASA) Physical Status I, II or III.

          3. Requires non-intubated, spontaneous breathing, moderate to deep sedation (NI MDS) for
             a magnetic resonance imaging (MRI) study with an intensivist, anesthesiologist or
             other proceduralist in attendance.

          4. Duration of the MRI scan is expected to take at least 20 minutes but no more than 3
             hours to complete

        Key Exclusion Criteria:

          1. Pregnant female subjects (including those with an indeterminate or positive pregnancy
             test); breastfeeding female subjects.

          2. Weight on Day 1 before randomization is less than the 10th percentile of weight for
             age and sex in the US and Japan or is greater than the 95th percentile of weight for
             age and sex in the US or greater than the 97th percentile of weight for age and sex in
             Japan based on sponsor-provided growth charts.

          3. Planned medical procedure during the MRI scan or post-MRI recovery period.

          4. Requires endotracheal intubation or laryngeal mask airway (LMA).

          5. Known allergy to eggs, egg products, soybeans or soybean products.

          6. SpO2 &lt;93 % on room air -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami / Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IU Health Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ibaraki Children Hospital</name>
      <address>
        <city>Mito</city>
        <state>Ibaraki</state>
        <zip>311-4145</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shikoku Medical Center for Children and Adults</name>
      <address>
        <city>Zentsuji</city>
        <state>Kagawa</state>
        <zip>765-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka Women's and Children's Hospital</name>
      <address>
        <city>Izumi-shi</city>
        <state>Osaka</state>
        <zip>594-1101</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shizuoka Children's Hospital</name>
      <address>
        <city>Shizuoka-shi</city>
        <state>Shizuoka</state>
        <zip>420 8660</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Children's Medical Center</name>
      <address>
        <city>Fuchu</city>
        <state>Tokyo</state>
        <zip>183-8561</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Center for Child Health and Development</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>157-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka City General Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C0801039</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 17, 2020</study_first_submitted>
  <study_first_submitted_qc>January 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>procedural sedation</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>propofol</keyword>
  <keyword>MRI</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

